Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. The company is focused on developing clinically validated branded cannabis products for the treatment of a variety of medical conditions. Zelira owns a leading pipeline of candidates in clinical development and a portfolio of products already launched into the market. These products are targeting large addressable markets for insomnia, chronic pain and autism.
Zelira has already launched two products, HOPETM, for patient symptoms associated with Autism Spectrum Disorder, in the US market and plans to launch the product into the Australian market in 2H, 2020. Zelira Therapeutics also owns the worlds first medicinal cannabis formulation for the treatment of chronic insomnia, which has been successfully validated in a randomised Phase 2 clinical trial. The product is on-track for launch in Australia and other global markets by Q3 2020.
Read more about Zelira Therapeutics
Osagie Imasogie | Chairman@Zelira Therapeutics
Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies. Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham.
Prior to this role at SmithKline, he was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals. He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Ilera Healthcare, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics and Trigenesis Therapeutics. Osagie has also been a Corporate Finance Partner in Price Waterhouse and a practicing attorney in a major US Law Firm.
Osagie is active in charitable and community pursuits and serves as a member of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art. Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also serves on the Law School’s Board of Overseers. In addition, he is a member of the Board of Trustees of the University of Pennsylvania and serves as the Chairman of the Budget & Finance Committee in addition to being a member of the Executive Committee. Osagie is a member of the New York State Bar.
Richard Hopkins | International Managing Director@Zelira Therapeutics
Dr Hopkins is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters. During his career Dr Hopkins has managed and overseen several strategic alliance and licensing deals with global pharmaceutical partners.
Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company. Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.
Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr Hopkins currently serves as a member of the Western Australian Ausbiotech Committee.